Dr Reddy's Parkinson drug launched in the US

Published On 2015-08-13 07:09 GMT   |   Update On 2015-08-13 07:09 GMT

Dr Reddy's Laboratories has launched the generic drug Pramipexole dihydrochloride in the strength of 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg post approval from USFDADr Reddy's Laboratories has recently announced the launch of its generic drug for Parkinson's treatment in the US market. The development is reported post approval from the US Food and Drug Administration received by the...

Login or Register to read the full article
Dr Reddy's Laboratories has launched the generic drug Pramipexole dihydrochloride in the strength of 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg post approval from USFDA

Dr Reddy's Laboratories has recently announced the launch of its generic drug for Parkinson's treatment in the US market. The development is reported post approval from the US Food and Drug Administration received by the company.

Dr Reddy’s Labs have made available the generic drug- Pramipexole dihydrochloride extended release tablets in the 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, as reported by the company to PTI.

The company's product is generic version of Mirapex ER tablets. "The Mirapex ER brand and generic had US sales of approximately USD 48.3 million MAT for the most recent twelve months ending in June 2015 according to IMS Health," it said.

The DRL product is available in bottle count sizes of 30, it added.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News